PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:US20220112181A1
公开(公告)日:2022-04-14
Invented are compounds of formula I
and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.
已发明的化合物为公式I的化合物以及其药用可接受的盐、酯和前药,这些化合物是DGAT2抑制剂。还提供了制备公式I化合物的方法,包含公式I化合物的药物组合物,以及使用这些化合物治疗肝脂肪变性、非酒精性脂肪肝炎(NASH)、纤维化、2型糖尿病、肥胖、高脂血症、高胆固醇血症、动脉粥样硬化、认知功能下降、痴呆、心肾疾病如慢性肾病和心力衰竭以及相关疾病和症状的方法,包括向需要的患者给予公式I的化合物。